Pharma News|Indian Pharma News|Pharma News Daily

NPPA NEWS UPDATES / DPCO NEWS UPDATES

Indian Pharma Companies - Indian Pharma Sector has a major role for GDP of India.

Indian Pharma News

Headline: " Pharma sector set to get formula right "

Summary: A 350-acre medical devices park is being set up at the SIPCOT industrial complex at Oragadam in Kancheepuram district with a potential to attract `3,500 crore in investments. A pharma park is on the anvil at Tindivanam in Villupuram district,which is expected to generate drugs and pharmaceutical products worth `2,000 crore annually. The pharmaceutical industry is bullish that the state can attract investments to the tune of $10billion as the size of the Indian pharma industry is projected to touch $130 billion by 2030.

Source: ET HealthWorld.com From The Economic Times
Date : 2023-08-01
Read More..wwwlink: https://health.economictimes.indiatimes.com/news/pharma/policy-regulations/pharma-sector-set-to-get-formula-right/102264559

Indian Pharma News

Headline: " Cipla to launch respiratory drugs by the end of this quarter; Expects over 2-3% revenue growth from new products in FY24 "

Summary: Interestingly, the company’s US business reported the highest-ever revenue of $ 222 million, registering a growth of 43% YoY growth driven by robust momentum in differentiated portfolios. Cipla on Wednesday announced its financial results for Q1FY24. The company reported a 45.1 percent rise in its consolidated net profit for the quarter ended June 2023 at ₹995.7 crore as compared to ₹696.4 crore in the corresponding quarter of the last year.

Source: FINANCIAL EXPRESS
Date : 2023-07-29
Read More..wwwlink: https://www.financialexpress.com/healthcare/cipla-to-launch-respiratory-drugs-by-the-end-of-this-quarter-expects-over-2-3-revenue-growth-from-new-products-in-fy24/3192250/

Indian Pharma News

Headline: " Dr Reddy’s to focus on continued growth of core businesses in FY24; Plans to increase presence in chronic segment "

Summary: eanwhile, the North America made for 47% of the total sales for Dr Reddy’s in the quarter, while 17% each came from India and Emerging markets. Europe contributed 8% to the total sales. Dr Reddy’s Laboratories on Wednesday announced its consolidated financial results for the quarter ended June 30, 2023. The pharma major reported an 18 per cent rise in its consolidated net profit to Rs 1,402.5 crore in the quarter as compared to Rs 1,187.6 crore in the same quarter last year.

Source: FINANCIAL EXPRESS
Date : 2023-07-29
Read More..wwwlink: https://www.financialexpress.com/healthcare/pharma-healthcare/dr-reddys-to-focus-on-continued-growth-of-core-businesses-in-fy24-plans-to-increase-presence-in-chronic-segment/3192238/

Indian Pharma News

Headline: " Ajanta Pharma stock jumps nearly 9% on strong Q1 results; Should you buy, sell or hold Ajanta Pharma shares? "

Summary: Ajanta Pharma shares surged today. Most analysts have recommended a ‘Buy’ rating on the stock. Ajanta Pharma share price jumped 8.7% to Rs 1,682.05 today after the company’s board approved the first interim dividend of Rs 315 crore for FY2024. The company’s net profit jumped 19.2% on-year to Rs 208.1 crore for the quarter ended June. Most analysts have recommended a ‘Buy’ rating on the stock. Ajanta Pharma shares have jumped 12% in the past one month and over 30% in the last one year.

Source: FINANCIAL EXPRESS
Date : 2023-07-28
Read More..wwwlink: https://www.financialexpress.com/market/ajanta-pharma-stock-jumps-nearly-9-on-strong-q1-results-should-you-buy-sell-or-hold-ajanta-pharma-shares/3190485/

Indian Pharma News

Headline: " Akums gets approval for triple combination diabetes treatment "

Summary: Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500 is specifically formulated for the treatment of diabetes and offers a number of pharmacological advantages. Akums Drugs and Pharmaceuticals Limited on Wednesday announced that it has secured approval for its triple combination diabetes treatment. Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500 comes as a more advanced treatment for diabetes, with much more efficacy and precision than monotherapy drugs that are currently in the market, the company said in a statement.

Source: FINANCIAL EXPRESS
Date : 2023-07-26
Read More..wwwlink: https://www.financialexpress.com/healthcare/pharma-healthcare/akums-gets-approval-for-triple-combination-diabetes-treatment/3187490/

Indian Pharma News

Headline: " Revenue of top domestic pharmaceutical firms to grow by 7-9 per cent in FY24: Icra "

Summary: The growth will be supported by an 8-10 per cent expansion in the domestic market and a 6-8 per cent rise in the US market, while revenues from the European and emerging markets are expected to increase by 3-5 per cent and 8-10 per cent, respectively, it noted. Revenue of top domestic pharmaceutical companies is likely to grow by 7-9 per cent in the current fiscal, according to rating agency Icra. The growth will be supported by an 8-10 per cent expansion in the domestic market and a 6-8 per cent rise in the US market, while revenues from the European and emerging markets are expected to increase by 3-5 per cent and 8-10 per cent, respectively, it noted.

Source: FINANCIAL EXPRESS
Date : 2023-07-26
Read More..wwwlink: https://www.financialexpress.com/industry/revenue-of-top-domestic-pharmaceutical-firms-to-grow-by-7-9-per-cent-in-fy24-icra/3187051/

Indian Pharma News

Headline: " Indian pharma exports to touch $22 billion this fiscal, Q1 exports stand at $5 billion "

Summary: HYDERABAD: Indian pharmaceutical exports are likely to touch $22 billion this fiscal largely owing to improving exports to and stabilising prices in the US market, which accounts for a third of India’s pharma exports, recording over 14.5% growth over last fiscal, forecasts Pharmaceuticals Export Promotion Council of India (Pharmexcil), a part of the ministry of commerce and industry.

Source: ET Bureau
Date : 2019-09-13
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-exports-may-touch-22-billion-in-fy-20-pharmexcil/articleshow/71111944.cms

Indian Pharma News

Headline: " Five ways pharmaceutical and healthcare sectors can be ‘Modified’ "

Summary: The Lok Sabha election results did not affect the pharma stocks but the Modi government can impact the pharma and healthcare sectors in several ways. GDP spend on healthcare: Increasing the expenditure on healthcare can be the most impactful measure that the government can undertake. The additional funds would be required for spending on strengthening the primary healthcare infrastructureNSE -3.43 % and building upon the secondary and tertiary public healthcare setup. IIndia spends 1.15 per cent of its GDP on healthcare and the government has targeted to increase it to 2.5 per cent by 2025.

Source: THE ECONOMIC TIMES
Date : 2019-05-30
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/five-ways-pharmaceutical-and-healthcare-sectors-can-be-modified/articleshow/69570924.cms

Indian Pharma News

Headline: " Indian Pharma’s incentives to do business in US on steady decline "

Summary: When Sun Pharma chief Dilip Shanghvi says he sees a big opportunity in China, the world’s second-largest drug market, it may be indicative of the unveiling of a new strategy at India's largest pharma company which could soon be mirrored by others in the sector. It’s an idea that’s been ripe for implementation for some time now. In recent years, there has been a consistent decline in incentive for Indian pharma companies to do business in the US — the world’s largest pharma market. First ..

Source: THE ECONOMIC TIMES
Date : 2019-05-16
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/indian-pharmas-incentives-to-do-business-in-us-on-steady-decline/articleshow/69352167.cms

Indian Pharma News

Headline: " Understanding the biosimilars opportunity for Indian pharma "

Summary: Biologics, a category of pharmaceuticals which has been around for more than a decade, is back on discussion forums given the huge global market potential in the next three to five years. Several drugs classified as biologics are expected to go off patent during this period thereby making way for their biosimilar counterparts. Indian pharma companies active in this field are expected to be among the biggest beneficiaries of this opportunity.

Source: THE ECONOMIC TIMES
Date : 2019-05-15
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/understanding-the-biosimilars-opportunity-for-indian-pharma/articleshow/69335230.cms

Indian Pharma News

Headline: " Sun, Dr Reddy's among 7 Indian pharma majors sued in US for price rigging "

Summary: MUMBAI: More than 40 US states filed lawsuits against pharma majors, including seven domestic companies, over collusion in inflating prices of widely prescribed generic medicines, in certain cases as high as 1,000%. The 500-page case filed by US states on May 10 charged global biggies like Teva, Pfizer, Sandoz and Mylan, as well as domestic companies like Sun Pharma’s US arm Taro, Zydus NSE -1.27 %, Lupin NSE 0.21 %, Aurobindo, Dr Reddy’s, Wockhardt and Glenmark NSE -1.57 % with conspiring to inflate prices of medicines, and stifling competition for generic drugs.

Source: THE ECONOMIC TIMES
Date : 2019-05-14
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/7-indian-pharma-cos-face-lawsuits-from-over-40-us-states/articleshow/69319125.cms

Indian Pharma News

Headline: " Why MSMEs should treat Intellectual Property Rights as assets "

Summary: Conventionally, Indian Micro, Small and Medium Enterprises (MSMEs) have relied on creating and protecting tangible assets-from land, machinery to office equipment-together with their revenue and receivables, to boost their valuation and prestige among their peers and in the industry. However, as per global experience, MSMEs have catapulted into the big league of large enterprises by transcending borders, that is, Multinational Corporations (MNCs), when they invest in creation and protection of i ..

Source: ET Bureau
Date : 2019-05-13
Read More..wwwlink: https://economictimes.indiatimes.com/small-biz/sme-sector/why-msmes-should-treat-intellectual-property-rights-as-assets/articleshow/69304077.cms

Indian Pharma News

Headline: " China's war on healthcare costs lures India's biggest drugmaker "

Summary: Sun Pharmaceutical Industries Ltd. is scouting for a partner in China to help it win a larger piece of the world’s second-largest drug market, where the government is on a mission to drive down healthcare costs.

Source: THE ECONOMIC TIMES BUREAU
Date : 2019-05-05
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/chinas-war-on-healthcare-costs-lures-indias-biggest-drugmaker/articleshow/69184122.cms

Indian Pharma News

Headline: " Cipla is undergoing a big transformation and is doing something it once eschewed "

Summary: An illustrated, coffee-table edition of the Bhagavad Gita sits open atop a wooden stand in the office of CiplaNSE -1.10 % managing director Umang Vohra, at the company’s plush headquarters in Mumbai’s Lower Parel. The cover has an illustration of the famous dialogue between Krishna and Arjuna in a chariot. It captures the setting of the hugely influential scripture, a treatise on dilemmas, decision-making and duty. It’s kept open so that the office’s occupant or visitors can easily browse throug ..

Source: ET Bureau
Date : 2019-05-05
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-is-undergoing-a-big-transformation-and-is-doing-something-it-once-eschewed/articleshow/69179068.cms

Indian Pharma News

Headline: " Substandard drugs are a bigger problem for India than fakes "

Summary: ET INTELLIGENCE GROUP: The US has blamed India for being a major source of counterfeit drugs globally, but for pharma companies in the country, substandard medicines pose a bigger problem than what has been flagged by their largest market overseas.

Source: THE ECONOMIC TIMES BUREAU
Date : 2019-05-02
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/substandard-drugs-are-a-bigger-problem-for-india-than-fakes/articleshow/69137983.cms

Indian Pharma News

Headline: " New legal risks emerge for Indian pharma "

Summary: Investors in Indian pharma companies may have become tolerant of the patent law suits and FDA clampdowns, but there is a steadily emerging set of law suits – class action suits, anti-trust suits and whistle-blower suits – that threaten to exponentially increase the risk in investing in pharma stocks. Price collusion, pay-for-delay arrangements and manufacturing malpractices are the issues that potentially invoke litigations involving these companies.

Source: THE ECONOMIC TIMES BUREAU
Date : 2019-04-19
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/new-legal-risks-emerge-for-indian-pharma/articleshow/68949069.cms

Indian Pharma News

Headline: " Can Glenmark Pharma taste success where its peers have not? "

Summary: ET Intelligence Group: One of the earliest Indian drugmakers to have focused on innovative R&D, Glenmark PharmaNSE 0.85 % is now spinning off its R&D business into a separate company that would be based in the US. Glenmark Pharma has hired a former executive from Gilead & Novartis to head the new company. All innovative molecules in the pipeline, including preclinical assets and technology, the R&D centres in Switzerland, Paramus, and Navi Mumbai, and the biologics manufacturing facility in Switzerland, along with 400 employees associated with innovative drug discovery will be part of the new company in the next six to nine months.

Source: ET Bureau
Date : 2019-03-25
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/can-glenmark-pharma-taste-success-where-its-peers-have-not/articleshow/68554865.cms

Indian Pharma News

Headline: " Pharma MNCs wary of illegal import of innovator drugs "

Summary: Hyderabad: Multinational pharmaceutical companies are crying foul over the illegal import of innovator drugs worth crores of rupees into the Indian market from neighbouring countries and sold by pharmacies, distributors and websites.

Source: ET Bureau
Date : 2019-03-21
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/pharma-mncs-wary-of-illegal-import-of-innovator-drugs/articleshow/68508366.cms

Indian Pharma News

Headline: " Pharma cos have not worked on compliance issues: Amit Rajan, Prosfora Tech "

Summary: We have been slipping on our compliance and even if the tide was turning with respect to pricing pressure easing down, our own GMP compliance problems have really let us down, said Amit Rajan, MD, Prosfora Technologies, in an interview with ET Now.

Source: ET Bureau
Date : 2019-03-18
Read More..wwwlink: https://economictimes.indiatimes.com/markets/expert-view/pharma-cos-have-not-worked-on-compliance-issues-amit-rajan-prosfora-tech/articleshow/68463356.cms

Indian Pharma News

Headline: " US FDA chief’s exit could impact Indian pharma "

Summary: The abrupt exit of the US FDA commissioner Scott Gottlieb after a nearly 2-year stint under the Trump administration throws Indian pharma into uncertainty on what would be the stance of the next commissioner on generics drug pricing, pace of approvals and regulatory inspections.

Source: THE ECONOMIC TIMES BUREAU
Date : 2019-03-07
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/us-fda-chiefs-exit-could-impact-indian-pharma/articleshow/68296155.cms

Indian Pharma News

Headline: " D G Shah founder of Indian Pharmaceutical Alliance dies at age 77 "

Summary: Dilip Shah, founder of the Indian Pharmaceutical Alliance (IPA) the organisation that represented the interests of Indian drug makers passed away in Mumbai on Friday. He was 77. Known in the industry as "DG", Mr Shah started the IPA when the Indian pharma companies were trying to find their feet in the global pharma landscape that was dominated by the multinational pharma companies predominantly based out of Europe and USA.

Source: ET Bureau
Date : 2019-02-22
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/d-g-shah-founder-of-indian-pharmaceutical-alliance-dies-at-age-77/articleshow/68107459.cms

Indian Pharma News

Headline: " Culture of ‘bending rules’ in India challenges U.S. drug agency "

Summary: Perched on the edge of a sheer rocky outcropping, Mylan NV’s flagship pharmaceutical factory looms over a patchwork of farmers’ fields like one of the medieval hill forts that dot the landscape in this part of India.

Source: THE ECONOMIC TIMES
Date : 2019-01-31
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/culture-of-bending-rules-in-india-challenges-u-s-drug-agency/articleshow/67769847.cms

Indian Pharma News

Headline: " Dr Reddy's Laboratories Ltd appoints Axis Bank ex-MD Shikha Sharma as independent director "

Summary: NEW DELHI: Pharma major Dr Reddy's Laboratories Thursday said it has appointed Axis BankNSE -0.75 %'s former MD and CEO Shikha Sharma as company's independent additional director for five years.

Source: THE ECONOMIC TIMES
Date : 2019-01-31
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-laboratories-ltd-appoints-axis-bank-ex-md-shikha-sharma-as-ind-director/articleshow/67776584.cms

Indian Pharma News

Headline: " Natco dares Novartis with new heart drug "

Summary: Mumbai: Hyderabad-based Natco PharmaNSE -0.14 % said it has launched in India valsartan-sacubitril, a drug used for heart ailment, under its brand name Valsac. In doing so, the homegrown drug maker has set the stage for a patent challenge from Swiss drug maker NovartisNSE 0.00 %, which is rapidly building on Vymada, its patented brand in India.

Source: THE ECONOMIC TIMES
Date : 2019-01-30
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-dares-novartis-with-new-heart-drug/articleshow/67749301.cms

Indian Pharma News

Headline: " Govt plans to make manufacturers pay for entire batch if single drug found substandard "

Summary: Once approved, the provision will be a part of the Drug and Cosmetics Act. Under the existing system, if a drug is found substandard, the drug inspector can initiate legal action against the manufacturer.

Source: Business Today
Date : 2019-01-27
Read More..wwwlink: https://www.businesstoday.in/sectors/pharma/govt-plans-make-manufacturers-pay-entire-batch-single-drug-found-substandard/story/314107.html

Indian Pharma News

Headline: " Aster DM Healthcare to invest Rs 650 crore in new hospitals "

Summary: Aster earned about Rs 1,000 crore from its India business last year and is likely to have over Rs 1,300 crore earnings in 2018-19 from the 11 facilities operational in India. Billionaire Dr Azad Moopen-promoted Aster DM Healthcare is planning to invest over Rs 650 crore in the next two years to take its total hospital bed capacity to 6,000 from the current 4,800 beds.

Source: Business Today
Date : 2019-01-18
Read More..wwwlink: https://www.businesstoday.in/sectors/pharma/aster-dm-healthcare-invest-rs-650-crore-new-hospitals/story/311239.html

Indian Pharma News

Headline: " Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab) "

Summary: Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies.

Source: WORLDPHARMANEWS
Date : 2019-01-17
Read More..wwwlink: http://www.worldpharmanews.com/amgen/4681-amgen-and-ucb-receive-positive-vote-from-fda-advisory-committee-in-favor-of-approval-for-evenity-romosozumab

Indian Pharma News

Headline: " Indian pharma industry records 9.4% growth in 2018, dispels GST gloom "

Summary: The domestic pharmaceutical industry bounced back to a nearly double-digit year-on-year growth in 2018 (9.4 per cent), after falling to an eight-year low (5.5 per cent) in the previous year. The industry’s size was Rs 1.29 trillion last year.

Source: Business Standard
Date : 2019-01-10
Read More..wwwlink: https://www.business-standard.com/article/companies/indian-pharma-industry-records-9-4-growth-in-2018-dispels-gst-gloom-119011000018_1.html

Indian Pharma News

Headline: " Zydus Cadila gets USFDA nod for antipsychotic drug "

Summary: New Delhi, Jan 8 () Zydus Cadila Tuesday said it has received final approval from the US health regulator to market antipsychotic drug Aripiprazole tablets. Zydus Cadila has received the approval from the United States Food and Drug Administration (USFDA) to market the drug in the strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, the company said in a BSE filing.

Source: THE ECONOMIC TIMES
Date : 2019-01-08
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-usfda-nod-for-antipsychotic-drug/articleshow/67434148.cms

Indian Pharma News

Headline: " Share market update: Pharma shares slip; Sun Pharma down nearly 3% "

Summary: NEW DELHI: The Nifty Pharma index was down 1.65 per cent at 8582.65 around 10:31 am on Wednesday with all its components trading in the red. Shares of Sun Pharmaceutical Industries (down 2.69 per cent), Piramal Enterprises (down 2.36 per cent), LupinNSE 0.54 % (down 2.01 per cent) and Cipla (down 1.84 per cent) were trading in the red.

Source: ETMarkets.com
Date : 2018-12-26
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/share-market-update-pharma-shares-slip-sun-pharma-down-nearly-3/articleshow/67251894.cms

Indian Pharma News

Headline: " Free pharma samples come under GST lens "

Summary: Top executives of India’s $37-billion pharmaceutical industry have a new destination on their frequent travel plan – Kanpur. The director-general of the intelligence wing for goods and services tax (GST) in Kanpur has issued summons to drug makers, asking for voluminous data related to supplies for the past year. The companies are being prodded to reverse claims of input tax credit in respect of free samples supplied as part of their promotion efforts.

Source: ET Bureau
Date : 2018-12-17
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/free-pharma-samples-come-under-gst-lens/articleshow/67134917.cms

Indian Pharma News

Headline: " India to boost food, pharma, IT, tourism exports in China’s first import only show "

Summary: India is eyeing giving a boost to its exports of food and agro productsNSE -0.23 %, pharmaceuticals, information technology (IT) and services such as tourism to China as it participates in the first China International Import Expo (CIIE).

Source: ET Bureau
Date : 2018-11-05
Read More..wwwlink: https://economictimes.indiatimes.com/news/economy/foreign-trade/india-to-boost-food-pharma-it-tourism-exports-in-chinas-first-import-only-show/articleshow/66512669.cms

Indian Pharma News

Headline: " Actis could step up investments in India’s green energy space "

Summary: Mumbai: Growth market-focused alternative investment firm Actis said India is one of its core investment markets where it has committed nearly a billion in the past 12 months, betting big on a fresh wave on renewable energy and continued advancement in fintech and consumer businesses compared to other emerging market peers.

Source: ET Bureau
Date : 2018-10-30
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/actis-could-step-up-investments-in-indias-green-energy-space/articleshow/66424173.cms

Indian Pharma News

Headline: " Desi pharma companies top in biosimilars globally "

Summary: MUMBAI: India is leading the global biosimilar pipeline, with the largest number of products launched in the country and emerging economies. Reliance Life Sciences tops the global pecking order, followed by Intas and Biocon.

Source: ET Bureau
Date : 2018-10-29
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/desi-pharma-companies-top-in-biosimilars-globally/articleshow/66410203.cms

Indian Pharma News

Headline: " Local pharma formulators to benefit from new USFDA generic guidance: Report "

Summary: The recent guidance from the US Food & Drug Administration (USFDA) on complex generics is expected to provide more clarity to US-focused Indian pharmaceutical formulators in preparing and submitting abbreviated new drug applications (ANDAs), says a report

Source: ET Bureau
Date : 2018-10-28
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/local-pharma-formulators-to-benefit-from-new-usfda-generic-guidance-report/articleshow/66399820.cms

Indian Pharma News

Headline: " Big pharma companies set to return to double-digit growth this fiscal: Crisil "

Summary: NEW DELHI: After two consecutive years of single-digit expansion, big Indian drug firms are expected to return to double-digit growth in the current fiscal aided by recovery in US sales, weakening of the rupee and revival of domestic demand, ratings agency Crisil NSE 0.51 % said.

Source: ET Bureau
Date : 2018-10-28
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/big-pharma-companies-set-to-return-to-double-digit-growth-this-fiscal-crisil/articleshow/66401562.cms

Indian Pharma News

Headline: " Zydus Cadila set to bag Kraft Heinz portfolio for Rs 4600 crore, announcement likely on Wednesday "

Summary: Zydus Cadila Group is set to acquire the consumer brand business of Kraft Heinz in India including the children's milk drink Complan for Rs 4500-4600 crore said multiple sources aware of the developments. A formal announcement could be this week, even as early as Wednesday. Once selected, Cadila may rope in a private equity partner for financing support. It had sent feelers to PE groups True North, Temasek, Warburg Pincus and Carlyle to partner them and may place its equity in a back-to-back deal. Mails sent to Cadila did not generate a response till the time of going to press. Sources said it has also reached out to some of the domestic banks and financial institutions for funding.

Source: THE ECONOMIC TIMES
Date : 2018-10-24
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-set-to-bag-kraft-heinz-portfolio-for-rs-4600-crore-announcement-likely-on-wednesday/articleshow/66338517.cms

Indian Pharma News

Headline: " Strides Pharma receives USFDA approval for antiepileptic drug Gabapentin "

Summary: Strides Pharma Science (Strides) Saturday announced that its global arm Strides Pharma Global Pte Singapore has received USFDA approval for Gabapentin Capsules. Gabapentin Capsules is a generic version of Neurontin Capsules of Pfizer Inc, a release said here.

Source: Business Standard
Date : 2018-10-20
Read More..wwwlink: https://www.business-standard.com/article/international/strides-pharma-receives-usfda-approval-for-antiepileptic-drug-gabapentin-118102000620_1.html

Indian Pharma News

Headline: " FII View | Foreign investors cautious on India, pharma & consumption attractive: Steven Birch "

Summary: According to the latest report by IMF, India is poised to grow at 7.4 percent in 2018 and 7.8 percent in 2019, making it the fastest growing economy among peers overtaking China. The US Fed is expected to raise the interest rate to 2.5 percent in December, 3 percent in 2019 and 3.5 percent in 2020, which could further make FPIs pull out money from India, Steven Birch, President & CEO, William O’Neil+Co, said in an interview with Moneycontrol’s Kshitij Anand.

Source: Moneycontrol.com
Date : 2018-10-19
Read More..wwwlink: https://www.moneycontrol.com/news/business/markets/fii-view-foreign-investors-cautious-on-india-pharma-consumption-attractive-steven-birch-3062721.html

Indian Pharma News

Headline: " How pharma packaging is helping to solve the patient compliance problem "

Summary: Medication packaging needs to make it as simple as possible to take the right dose at the right time and empower health professionals to track at-home usage.

Source: ETHealthWorld
Date : 2018-10-18
Read More..wwwlink: https://health.economictimes.indiatimes.com/news/pharma/how-pharma-packaging-is-helping-to-solve-the-patient-compliance-problem/66271299

Indian Pharma News

Headline: " Sun Pharma Q2 PAT seen up 17.1% YoY to Rs. 1,070 cr: HDFC Securities "

Summary: Net Sales are expected to increase by 12.5 percent Y-o-Y (up 3.6 percent Q-o-Q) to Rs. 7,480 crore, according to HDFC Securities.

Source: Moneycontrol.com
Date : 2018-10-18
Read More..wwwlink: https://www.moneycontrol.com/news/business/earnings/sun-pharma-q2-pat-seen-up-17-1-yoy-to-rs-1070-cr-hdfc-securities-3057011.html

Indian Pharma News

Headline: " Piramal considers $1-billion pharma services business sale: Reports But analysts say pharma services constitute 6-7 percent of Piramal's revenues and is a drag on overall pharma business. "

Summary: Pharma and financial services focused company, Piramal Enterprises, is said to be weighing the sale of its pharmaceutical services business for $1 billion, according to several media reports. The reports, which the company termed "market speculation", indicate that it had sent feelers to investment bankers.

Source: Moneycontrol.com
Date : 2018-10-17
Read More..wwwlink: https://www.moneycontrol.com/news/business/companies/piramal-considers-1-billion-pharma-services-business-sale-reports-3054181.html

Indian Pharma News

Headline: " Big pharma companies propose launch of low priced ‘second brands’ for Ayushman Bharat health insurance scheme "

Summary: NEW DELHI: In a move that may bring huge relief to patients, multinational pharmaceutical companies like Pfizer, GlaxoSmithKline Pharma and Abbott have proposed to launch a low priced "second brand" of their products which can be introduced into government's flagship Ayushman Bharat health health insurance scheme, sources said.

Source: The Time of India|TNN
Date : 2018-10-16
Read More..wwwlink: https://timesofindia.indiatimes.com/india/big-pharma-proposes-launch-of-low-priced-second-brands-for-ayushman-bharat-health-insurance-scheme/articleshow/66229879.cms

Indian Pharma News

Headline: " Pharma stocks for defensive bias or to gain from weak rupee? Must read this "

Summary: How is the health of your portfolio after the recent selloff in equities? If you are planning to give your portfolio a defensive tweak in view of the multiple headwinds ahead, pharma is definitely one space to look at. Pharma is also in focus as a sharp drop in the rupee this year has turned investor focus on export-heavy businesses. But one needs to be selective and cautious. Select names from this sector such as Merck, Valiant Organics, Albert David and Kilitch Drugs have rallied between 60 and 110 per cent so far this year.

Source: The Economic Times
Date : 2018-10-16
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/pharma-stocks-for-defensive-bias-or-to-gain-from-weak-rupee-must-read-this/articleshow/66240064.cms

Indian Pharma News

Headline: " Pharma shares in focus; Dr Reddy's, Biocon, Lupin, Natco Pharma up over 3% "

Summary: Shares of pharmaceutical were in focus in an otherwise subdued market on Monday with Nifty Pharma index gaining nearly 2% against 0.17% decline in the Nifty 50 at 09:36 am.

Source: SI Reporter,Mumbai by Business Standard News
Date : 2018-10-15
Read More..wwwlink: https://www.business-standard.com/article/markets/pharma-shares-in-focus-dr-reddy-s-biocon-lupin-natco-pharma-up-over-3-118101500145_1.html

Indian Pharma News

Headline: " Sun pharma invests 120 crore in Assam to set up production line "

Summary: GUWAHATI: Pharmaceutical Company, Sun PharmaNSE 0.66 % has invested Rs 120 crore in Assam to set up production line which will boost the company’s capacity to manufacture liquid vials, injectable, eye drops and tablets.

Source: ET Bureau
Date : 2018-10-13
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-invests-120-crore-in-assam-to-set-up-production-line/articleshow/66196378.cms

Indian Pharma News

Headline: " Drug makers may have to pay 5 times more for pharma imports "

Summary: NEW DELHI: Drug makers importing medicines may soon have to pay the government up to five times more to register their products here and get their overseas manufacturing facilities audited by the Indian regulator. The move aims to increase domestic manufacturing of medicines.

Source: ET Bureau
Date : 2018-10-13
Read More..wwwlink: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/drug-makers-may-have-to-pay-5-times-more-for-pharma-imports/articleshow/66190163.cms

Indian Pharma News

Headline: " Share market update:Pharma shares mixed; Divi's Labs, Lupin shares in green "

Summary: New Delhi: Pharma shares were trading mixed in the Friday's session with the Nifty Pharma index trading 0.49 per cent up at 9,535 around 12:56 pm on Friday. Shares of Divi's Laboratories (up 2.53 per cent), Lupin (up 1.42 per cent), Piramal Enterprises (up 1.17 per cent) and Cadila Healthcare (up 1.16 per cent) were the top gainers in the index. Aurobindo Pharma (down 1.62 per cent), Glenmark Pharmaceuticals (down 0.35 per cent), Biocon (down 0.29 per cent) and Dr. Reddy's La ..

Source: ETMarkets.com
Date : 2018-10-12
Read More..wwwlink: https://economictimes.indiatimes.com/markets/stocks/news/share-market-updatepharma-shares-mixed-divis-labs-lupin-shares-in-green/articleshow/66178632.cms

Indian Pharma News

Headline: " GE Healthcare sees future in precision health; inks partnership to support Ayushman Bharat "

Summary: As GE Healthcare prepares itself to become a separate standalone company outside of GE next year, its president and CEO Kieran Murphy reiterates its position at being seen as one who is focussed on precision health in addition to helping hospitals achieve better clinical outcomes.

Source: E Kumar Sharma New Delhi - businesstoday.in
Date : 2018-10-09
Read More..wwwlink: https://www.businesstoday.in/sectors/pharma/ge-healthcare-sees-future-in-precision-health-inks-partnership-to-support-ayushman-bharat/story/284475.html